New combo therapy targets hard-to-treat liver cancer

NCT ID NCT04238637

Ongoing Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Dec 10, 2025 · Last updated May 20, 2026 · Updated 18 times

Summary

This study tests whether adding immunotherapy drugs (durvalumab alone or with tremelimumab) to a type of internal radiation therapy (Y-90 SIRT) can shrink tumors in people with advanced bile duct cancer that has not spread beyond the liver. About 50 adults with this rare liver cancer will take part. The goal is to see if the combination improves response rates and is safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Clinic Essen Center

Essen, Germany
Hannover Medical School

Hanover, Germany
Munich Clinic Bogenhausen

Munich, Germany
University Hospital Dresden

Dresden, Germany
University Hospital Essen

Essen, Germany
University Hospital Halle

Halle, Germany
University Hospital Jena

Jena, Germany
University Hospital Munich Grosshadern

Munich, Germany

Conditions

Explore the condition pages connected to this study.

INTRAHEPATIC CHOLANGIOCARCINOMA